Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Rocco

Showing results (151-160 of 214) with videos related to

Pageof 22
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 13, 2015
Long-term Effects of Frequent Nocturnal Hemodialysis on Mortality: The Frequent Hemodialysis Network (FHN) Nocturnal TrialMichael V Rocco, John T Daugirdas, Tom Greene, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 21, 2011
Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African AmericansBarry I Freedman, Carl D Langefeld, Mariana Murea, et al.
Journal of Hypertension|May 7, 2020
Outcomes in adults with systolic blood pressure between 130 and 139 mmHg in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial and Systolic Blood Pressure Intervention TrialGabriel Contreras, Lingyi Lu, Leonardo Tamariz, et al.
Kidney International|June 15, 2012
Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal diseaseBarry I Freedman, Carl D Langefeld, Jolyn Turner, et al.
Annals of Epidemiology|April 29, 1998
The Kidney Outcomes Prediction and Evaluation (KOPE) study: a prospective cohort investigation of patients undergoing hemodialysis. Study design and baseline characteristicsM A Sevick, G S Tell, S A Shumaker, et al.
Journal of the American Society of Nephrology : JASN|February 9, 2013
Risk of vascular access complications with frequent hemodialysisRita S Suri, Brett Larive, Susan Sherer, et al.
BMC Nephrology|January 24, 2016
Cognitive changes associated with switching to frequent nocturnal hemodialysis or renal transplantationBradley S Dixon, John M VanBuren, James R Rodrigue, et al.
Research Square|October 3, 2025
An Observational Study of SGLT2 Inhibitors and Their Use in Autosomal Dominant Tubulointerstitial Kidney DiseaseKendrah O Kidd, Adrienne H Williams, Elhussein A E Elhassan, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 1, 2020
Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKDRakesh Malhotra, Ronit Katz, Vasantha Jotwani, et al.
Kidney International Reports|August 1, 2017
<i>APOL1</i> renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention TrialBarry I Freedman, Michael V Rocco, Jeffrey T Bates, et al.
Pageof 22

Showing results (151-160 of 214) with videos related to

Sort By:
Pageof 22
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 13, 2015
Long-term Effects of Frequent Nocturnal Hemodialysis on Mortality: The Frequent Hemodialysis Network (FHN) Nocturnal TrialMichael V Rocco, John T Daugirdas, Tom Greene, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 21, 2011
Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African AmericansBarry I Freedman, Carl D Langefeld, Mariana Murea, et al.
Journal of Hypertension|May 7, 2020
Outcomes in adults with systolic blood pressure between 130 and 139 mmHg in Action to Control Cardiovascular Risk in Diabetes Blood Pressure trial and Systolic Blood Pressure Intervention TrialGabriel Contreras, Lingyi Lu, Leonardo Tamariz, et al.
Kidney International|June 15, 2012
Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal diseaseBarry I Freedman, Carl D Langefeld, Jolyn Turner, et al.
Annals of Epidemiology|April 29, 1998
The Kidney Outcomes Prediction and Evaluation (KOPE) study: a prospective cohort investigation of patients undergoing hemodialysis. Study design and baseline characteristicsM A Sevick, G S Tell, S A Shumaker, et al.
Journal of the American Society of Nephrology : JASN|February 9, 2013
Risk of vascular access complications with frequent hemodialysisRita S Suri, Brett Larive, Susan Sherer, et al.
BMC Nephrology|January 24, 2016
Cognitive changes associated with switching to frequent nocturnal hemodialysis or renal transplantationBradley S Dixon, John M VanBuren, James R Rodrigue, et al.
Research Square|October 3, 2025
An Observational Study of SGLT2 Inhibitors and Their Use in Autosomal Dominant Tubulointerstitial Kidney DiseaseKendrah O Kidd, Adrienne H Williams, Elhussein A E Elhassan, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 1, 2020
Urine Markers of Kidney Tubule Cell Injury and Kidney Function Decline in SPRINT Trial Participants with CKDRakesh Malhotra, Ronit Katz, Vasantha Jotwani, et al.
Kidney International Reports|August 1, 2017
<i>APOL1</i> renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention TrialBarry I Freedman, Michael V Rocco, Jeffrey T Bates, et al.
Pageof 22